Fatty Acid Amide Hydrolase (FAAH) inhibition reduces L-3,4- dihydroxyphenylalanine-induced hyperactivity in the 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-lesioned non-human primate model of Parkinson's disease

Journal of Pharmacology and Experimental Therapeutics

Volumn 336, Issue 2, 2011, Pages 423-430

  Johnston, Tom H ^a,b   Huot, Philippe ^b   Fox, Susan H ^c   Wakefield, James D ^d   Sykes, Kristine A ^d   Bartolini, Wilmin P ^d   Milne, G Todd ^d   Pearson, James P ^d   Brotchie, Jonathan M ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c TORONTO WESTERN HOSPITAL   (Canada)

^d IRONWOOD PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ANANDAMIDE; BENSERAZIDE PLUS LEVODOPA; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; DOPA; FATTY ACID AMIDASE; N OLEOYLETHANOLAMINE; N PALMITOYLETHANOLAMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DRUG EFFECT; DYSKINESIA; ENZYME INHIBITION; FEMALE; HYPERACTIVITY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NONHUMAN; PARKINSON DISEASE; PRIMATE; PRIORITY JOURNAL; PSYCHOSIS;

AMIDOHYDROLASES; ANIMALS; BENZAMIDES; CALLITHRIX; CARBAMATES; DISEASE MODELS, ANIMAL; DYSKINESIA, DRUG-INDUCED; ENZYME INHIBITORS; ETHANOLAMINES; FEMALE; LEVODOPA; MOTOR ACTIVITY; MPTP POISONING; PALMITIC ACIDS; PSYCHOSES, SUBSTANCE-INDUCED;

EID: 78751482833     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.169532     Document Type: Article

References (42)

1. Ahn K, Johnson DS, Mileni M, Beidler D, Long JZ, McKinney MK, Weerapana E, Sadagopan N, Liimatta M, Smith SE, et al. (2009) Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. Chem Biol 16:411-420.
2. Barraud Q, Lambrecq V, Forni C, McGuire S, Hill M, Bioulac B, Balzamo E, Bezard E, Tison F, and Ghorayeb I (2009) Sleep disorders in Parkinson's disease: the contribution of the MPTP non-human primate model. Exp Neurol 219:574-582.
3. Bisogno T, Berrendero F, Ambrosino G, Cebeira M, Ramos JA, Fernandez-Ruiz JJ, and Di Marzo V (1999) Brain regional distribution of endocannabinoids: implications for their biosynthesis and biological function. Biochem Biophys Res Commun 256:377-380. (Pubitemid 29298893)
4. Boyce S, Rupniak NM, Steventon MJ, and Iversen SD (1990) Nigrostriatal damage is required for induction of dyskinesias by L-DOPA in squirrel monkeys. Clin Neuropharmacol 13:448-458. (Pubitemid 20285578)
5. Cenci MA (2007) Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia. Trends Neurosci 30:236-243.
6. Chu ZL, Carroll C, Chen R, Alfonso J, Gutierrez V, He H, Lucman A, Xing C, Sebring K, Zhou J, et al. (2010) N-oleoyldopamine enhances glucose homeostasis through the activation of GPR119. Mol Endocrinol 24:161-170.
7. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, and Gilula NB (1996) Molecular characterization of an enzyme that degrades neuromodulatory fattyacid amides. Nature 384:83-87.
8. Di Marzo V (2009) The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation. Pharmacol Res 60:77-84.
9. Di Marzo V, Hill MP, Bisogno T, Crossman AR, and Brotchie JM (2000) Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB J 14:1432-1438.
10. Evans AH and Lees AJ (2004) Dopamine dysregulation syndrome in Parkinson's disease. Curr Opin Neurol 17:393-398.
11. Evans AH, Pavese N, Lawrence AD, Tai YF, Appel S, Doder M, Brooks DJ, Lees AJ, and Piccini P (2006) Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol 59:852-858. (Pubitemid 43673163)
12. Fegley D, Gaetani S, Duranti A, Tontini A, Mor M, Tarzia G, and Piomelli D (2005) Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3′-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther 313:352-358.
13. Fox SH, Brotchie JM, and Lang AE (2008) Non-dopaminergic treatments in development for Parkinson's disease. Lancet Neurol 7:927-938.
14. Fox SH and Lang AE (2008) Levodopa-related motor complications- phenomenology. Mov Disord 23 (Suppl 3):S509-S514.
15. Fox SH, Visanji NP, Johnston TH, Gomez-Ramirez J, Voon V, and Brotchie JM (2006) Dopamine receptor agonists and levodopa and inducing psychosis-like behavior in the MPTP primate model of Parkinson disease. Arch Neurol 63:1343-1344.
16. Gobbi G, Bambico FR, Mangieri R, Bortolato M, Campolongo P, Solinas M, Cassano T, Morgese MG, Debonnel G, Duranti A, et al. (2005) Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci USA 102:18620-18625.
17. Gubellini P, Picconi B, Bari M, Battista N, Calabresi P, Centonze D, Bernardi G, Finazzi-Agrò A, and Maccarrone M (2002) Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. J Neurosci 22:6900-6907.
18. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, and Rice KC (1991) Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 11:563-583.
19. Justinova Z, Mangieri RA, Bortolato M, Chefer SI, Mukhin AG, Clapper JR, King AR, Redhi GH, Yasar S, Piomelli D, et al. (2008) Fatty acid amide hydrolase inhibition heightens anandamide signaling without producing reinforcing effects in primates. Biol Psychiatry 64:930-937.
20. Kathuria S, Gaetani S, Fegley D, Valiño F, Duranti A, Tontini A, Mor M, Tarzia G, La Rana G, Calignano A, et al. (2003) Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9:76-81.
21. Kinsey SG, Long JZ, O'Neal ST, Abdullah RA, Poklis JL, Boger DL, Cravatt BF, and Lichtman AH (2009) Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain. J Pharmacol Exp Ther 330:902-910.
22. Kreitzer AC and Malenka RC (2007) Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. Nature 445:643-647.
23. Lee J, Di Marzo V, and Brotchie JM (2006) A role for vanilloid receptor 1 (TRPV1) and endocannabinnoid signalling in the regulation of spontaneous and L-DOPA induced locomotion in normal and reserpine-treated rats. Neuropharmacology 51:557-565.
24. Lichtman AH, Leung D, Shelton CC, Saghatelian A, Hardouin C, Boger DL, and Cravatt BF (2004) Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity. J Pharmacol Exp Ther 311:441-448. (Pubitemid 39391527)
25. Maccarrone M, Gubellini P, Bari M, Picconi B, Battista N, Centonze D, Bernardi G, Finazzi- Agrò A, and Calabresi P (2003) Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism. J Neurochem 85:1018-1025.
26. Mascia P, Pistis M, Justinova Z, Panlilio LV, Luchicchi A, Lecca S, Scherma M, Fratta W, Fadda P, Barnes C, et al. (2010) Blockade of nicotine reward and reinstatement by activation of α-type peroxisome proliferator-activated receptors. Biol Psychiatry, doi: 10.1016/j.biopsych.2010. 07.009.
27. McKinney MK and Cravatt BF (2005) Structure and function of fatty acid amide hydrolase. Annu Rev Biochem 74:411-432.
28. Morgese MG, Cassano T, Cuomo V, and Giuffrida A (2007) Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors. Exp Neurol 208:110-119.
29. Naidu PS, Varvel SA, Ahn K, Cravatt BF, Martin BR, and Lichtman AH (2007) Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality. Psychopharmacology 192:61-70.
30. O'Sullivan SS, Evans AH, and Lees AJ (2009) Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management. CNS Drugs 23:157-170.
31. Piomelli D, Tarzia G, Duranti A, Tontini A, Mor M, Compton TR, Dasse O, Monaghan EP, Parrott JA, and Putman D (2006) Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). CNS Drug Rev 12:21-38.
32. Racette BA, Hartlein JM, Hershey T, Mink JW, Perlmutter JS, and Black KJ (2002) Clinical features and comorbidity of mood fluctuations in Parkinson's disease. J Neuropsychiatry Clin Neurosci 14:438-442.
33. Sharkey KA, Cristino L, Oland LD, Van Sickle MD, Starowicz K, Pittman QJ, Guglielmotti V, Davison JS, and Di Marzo V (2007) Arvanil, anandamide and N-arachidonoyl-dopamine (NADA) inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret. Eur J Neurosci 25:2773-2782. (Pubitemid 46888837)
34. Sieradzan KA, Fox SH, Hill M, Dick JP, Crossman AR, and Brotchie JM (2001) Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology 57:2108-2111.
35. Tourino C, Oveisi F, Lockney J, Piomelli D, and Maldonado R (2010) FAAH deficiency promotes energy storage and enhances the motivation for food. Int J Obes (Lond) 34:557-568.
36. Tzavara ET, Li DL, Moutsimilli L, Bisogno T, Di Marzo V, Phebus LA, Nomikos GG, and Giros B (2006) Endocannabinoids activate transient receptor potential vanilloid 1 receptors to reduce hyperdopaminergia-related hyperactivity: therapeutic implications. Biol Psychiatry 59:508-515.
37. van der Stelt M and Di Marzo V (2004) Endovanilloids. Putative endogenous ligands of transient receptor potential vanilloid 1 channels. Eur J Biochem 271:1827-1834.
38. van der Stelt M, Fox SH, Hill M, Crossman AR, Petrosino S, Di Marzo V, and Brotchie JM (2005) A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease. FASEB J 19:1140-1142.
39. Visanji NP, Fox SH, Johnston TH, Millan MJ, and Brotchie JM (2009) α1-Adrenoceptors mediate dihydroxyphenylalanine-induced activity in 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-lesioned macaques. J Pharmacol Exp Ther 328:276-283.
40. Visanji NP, Gomez-Ramirez J, Johnston TH, Pires D, Voon V, Brotchie JM, and Fox SH (2006) Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Mov Disord 21:1879-1891. (Pubitemid 44848934)
41. Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M, Voon V, Whetteckey J, Wunderlich GR, and Lang AE (2010) Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 67:589-595.
42. Whyte LS, Ryberg E, Sims NA, Ridge SA, Mackie K, Greasley PJ, Ross RA, and Rogers MJ (2009) The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo. Proc Natl Acad Sci USA 106:16511-16516.